 | • レポートコード：MRC2-11QY02565 • 出版社/出版日：QYResearch / 2020年11月20日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥561,600 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥842,400 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,123,200 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗炎症ペプチドのグローバル市場について調査・分析したレポートです。種類別（心血管疾患、胃腸疾患、皮膚疾患、神経疾患、耳鼻咽喉科疾患・眼科、呼吸器疾患・肺疾患、腎疾患、リウマチ・自己免疫疾患、移植）市場規模、用途別（病院用、診療所用、家庭用、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗炎症ペプチドの競争状況、市場シェア ・世界の抗炎症ペプチド市場：種類別市場規模 2015年-2020年（心血管疾患、胃腸疾患、皮膚疾患、神経疾患、耳鼻咽喉科疾患・眼科、呼吸器疾患・肺疾患、腎疾患、リウマチ・自己免疫疾患、移植） ・世界の抗炎症ペプチド市場：種類別市場規模予測 2021年-2026年（心血管疾患、胃腸疾患、皮膚疾患、神経疾患、耳鼻咽喉科疾患・眼科、呼吸器疾患・肺疾患、腎疾患、リウマチ・自己免疫疾患、移植） ・世界の抗炎症ペプチド市場：用途別市場規模 2015年-2020年（病院用、診療所用、家庭用、その他） ・世界の抗炎症ペプチド市場：用途別市場規模予測 2021年-2026年（病院用、診療所用、家庭用、その他） ・北米の抗炎症ペプチド市場分析：米国、カナダ ・ヨーロッパの抗炎症ペプチド市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗炎症ペプチド市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗炎症ペプチド市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗炎症ペプチド市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Mylan Pharmaceuticals、Novartis AG、Rogne Bioscience、Merck Serono、F4 Pharma、Araim Pharmaceuticals, Inc.、Digna Biotech、Abbvie Corporation ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Anti-inflammatory peptides also known as antiflammins inhibit inflammation of a mammal’s skin, lacerations of the musculature, mucous membranes, or injury into the air spaces of the lungs. Anti-inflammatory peptides act by hindering synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions. Anti-Inflammatory peptides are used to treat diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and other autoimmune diseases.
North America has dominated the entire market in 2014, as it has presence of technologically updated systems, strong research & development, and high patient awareness levels in this region. Latin America is also expected to grow at a healthy rate as a result of increase in both private and public associations, causing an increase in the investment, thereby boosting the demand for the anti-inflammatory peptides. However, the Asia Pacific region is expected to witness lucrative growth during the forecast period owing to the rapidly improving healthcare infrastructure in the growing economies of India and China. Growing patient awareness levels among the population of this region coupled with high unmet needs of the patients is expected to further drive this region.
Market Analysis and Insights: Global Anti-Inflammatory Peptides Market
The global Anti-Inflammatory Peptides market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anti-Inflammatory Peptides Scope and Market Size
Anti-Inflammatory Peptides market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Inflammatory Peptides market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-Inflammatory Peptides market is segmented into
Cardiovascular Diseases
Gastrointestinal Diseases
Dermatological Diseases
Neurological Diseases
Otorhino Diseases & Ophthalmological
Respiratory Diseases & Pulmonary
Renal Diseases
Rheumatological & Autoimmune Diseases
Transplantation
Segment by Application, the Anti-Inflammatory Peptides market is segmented into
Hospital Use
Clinic Use
Household
Other
Regional and Country-level Analysis
The Anti-Inflammatory Peptides market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-Inflammatory Peptides market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anti-Inflammatory Peptides Market Share Analysis
Anti-Inflammatory Peptides market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Inflammatory Peptides business, the date to enter into the Anti-Inflammatory Peptides market, Anti-Inflammatory Peptides product introduction, recent developments, etc.
The major vendors covered:
Mylan Pharmaceuticals
Novartis AG
Rogne Bioscience
Merck Serono
F4 Pharma
Araim Pharmaceuticals, Inc.
Digna Biotech
Abbvie Corporation
1 Study Coverage
1.1 Anti-Inflammatory Peptides Product Introduction
1.2 Market Segments
1.3 Key Anti-Inflammatory Peptides Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-Inflammatory Peptides Market Size Growth Rate by Type
1.4.2 Cardiovascular Diseases
1.4.3 Gastrointestinal Diseases
1.4.4 Dermatological Diseases
1.4.5 Neurological Diseases
1.4.6 Otorhino Diseases & Ophthalmological
1.4.7 Respiratory Diseases & Pulmonary
1.4.8 Renal Diseases
1.4.9 Rheumatological & Autoimmune Diseases
1.4.10 Transplantation
1.5 Market by Application
1.5.1 Global Anti-Inflammatory Peptides Market Size Growth Rate by Application
1.5.2 Hospital Use
1.5.3 Clinic Use
1.5.4 Household
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-Inflammatory Peptides Market Size, Estimates and Forecasts
2.1.1 Global Anti-Inflammatory Peptides Revenue 2015-2026
2.1.2 Global Anti-Inflammatory Peptides Sales 2015-2026
2.2 Global Anti-Inflammatory Peptides, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-Inflammatory Peptides Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-Inflammatory Peptides Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-Inflammatory Peptides Competitor Landscape by Players
3.1 Anti-Inflammatory Peptides Sales by Manufacturers
3.1.1 Anti-Inflammatory Peptides Sales by Manufacturers (2015-2020)
3.1.2 Anti-Inflammatory Peptides Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-Inflammatory Peptides Revenue by Manufacturers
3.2.1 Anti-Inflammatory Peptides Revenue by Manufacturers (2015-2020)
3.2.2 Anti-Inflammatory Peptides Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-Inflammatory Peptides Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-Inflammatory Peptides Revenue in 2019
3.2.5 Global Anti-Inflammatory Peptides Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-Inflammatory Peptides Price by Manufacturers
3.4 Anti-Inflammatory Peptides Manufacturing Base Distribution, Product Types
3.4.1 Anti-Inflammatory Peptides Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-Inflammatory Peptides Product Type
3.4.3 Date of International Manufacturers Enter into Anti-Inflammatory Peptides Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-Inflammatory Peptides Market Size by Type (2015-2020)
4.1.1 Global Anti-Inflammatory Peptides Sales by Type (2015-2020)
4.1.2 Global Anti-Inflammatory Peptides Revenue by Type (2015-2020)
4.1.3 Anti-Inflammatory Peptides Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-Inflammatory Peptides Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-Inflammatory Peptides Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-Inflammatory Peptides Revenue Forecast by Type (2021-2026)
4.2.3 Anti-Inflammatory Peptides Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-Inflammatory Peptides Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-Inflammatory Peptides Market Size by Application (2015-2020)
5.1.1 Global Anti-Inflammatory Peptides Sales by Application (2015-2020)
5.1.2 Global Anti-Inflammatory Peptides Revenue by Application (2015-2020)
5.1.3 Anti-Inflammatory Peptides Price by Application (2015-2020)
5.2 Anti-Inflammatory Peptides Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-Inflammatory Peptides Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-Inflammatory Peptides Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-Inflammatory Peptides Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-Inflammatory Peptides by Country
6.1.1 North America Anti-Inflammatory Peptides Sales by Country
6.1.2 North America Anti-Inflammatory Peptides Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-Inflammatory Peptides Market Facts & Figures by Type
6.3 North America Anti-Inflammatory Peptides Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-Inflammatory Peptides by Country
7.1.1 Europe Anti-Inflammatory Peptides Sales by Country
7.1.2 Europe Anti-Inflammatory Peptides Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-Inflammatory Peptides Market Facts & Figures by Type
7.3 Europe Anti-Inflammatory Peptides Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-Inflammatory Peptides by Region
8.1.1 Asia Pacific Anti-Inflammatory Peptides Sales by Region
8.1.2 Asia Pacific Anti-Inflammatory Peptides Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-Inflammatory Peptides Market Facts & Figures by Type
8.3 Asia Pacific Anti-Inflammatory Peptides Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-Inflammatory Peptides by Country
9.1.1 Latin America Anti-Inflammatory Peptides Sales by Country
9.1.2 Latin America Anti-Inflammatory Peptides Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-Inflammatory Peptides Market Facts & Figures by Type
9.3 Central & South America Anti-Inflammatory Peptides Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-Inflammatory Peptides by Country
10.1.1 Middle East and Africa Anti-Inflammatory Peptides Sales by Country
10.1.2 Middle East and Africa Anti-Inflammatory Peptides Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-Inflammatory Peptides Market Facts & Figures by Type
10.3 Middle East and Africa Anti-Inflammatory Peptides Market Facts & Figures by Application
11 Company Profiles
11.1 Mylan Pharmaceuticals
11.1.1 Mylan Pharmaceuticals Corporation Information
11.1.2 Mylan Pharmaceuticals Description and Business Overview
11.1.3 Mylan Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Mylan Pharmaceuticals Anti-Inflammatory Peptides Products Offered
11.1.5 Mylan Pharmaceuticals Related Developments
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Description and Business Overview
11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis AG Anti-Inflammatory Peptides Products Offered
11.2.5 Novartis AG Related Developments
11.3 Rogne Bioscience
11.3.1 Rogne Bioscience Corporation Information
11.3.2 Rogne Bioscience Description and Business Overview
11.3.3 Rogne Bioscience Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Rogne Bioscience Anti-Inflammatory Peptides Products Offered
11.3.5 Rogne Bioscience Related Developments
11.4 Merck Serono
11.4.1 Merck Serono Corporation Information
11.4.2 Merck Serono Description and Business Overview
11.4.3 Merck Serono Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Merck Serono Anti-Inflammatory Peptides Products Offered
11.4.5 Merck Serono Related Developments
11.5 F4 Pharma
11.5.1 F4 Pharma Corporation Information
11.5.2 F4 Pharma Description and Business Overview
11.5.3 F4 Pharma Sales, Revenue and Gross Margin (2015-2020)
11.5.4 F4 Pharma Anti-Inflammatory Peptides Products Offered
11.5.5 F4 Pharma Related Developments
11.6 Araim Pharmaceuticals, Inc.
11.6.1 Araim Pharmaceuticals, Inc. Corporation Information
11.6.2 Araim Pharmaceuticals, Inc. Description and Business Overview
11.6.3 Araim Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Products Offered
11.6.5 Araim Pharmaceuticals, Inc. Related Developments
11.7 Digna Biotech
11.7.1 Digna Biotech Corporation Information
11.7.2 Digna Biotech Description and Business Overview
11.7.3 Digna Biotech Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Digna Biotech Anti-Inflammatory Peptides Products Offered
11.7.5 Digna Biotech Related Developments
11.8 Abbvie Corporation
11.8.1 Abbvie Corporation Corporation Information
11.8.2 Abbvie Corporation Description and Business Overview
11.8.3 Abbvie Corporation Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Abbvie Corporation Anti-Inflammatory Peptides Products Offered
11.8.5 Abbvie Corporation Related Developments
11.1 Mylan Pharmaceuticals
11.1.1 Mylan Pharmaceuticals Corporation Information
11.1.2 Mylan Pharmaceuticals Description and Business Overview
11.1.3 Mylan Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Mylan Pharmaceuticals Anti-Inflammatory Peptides Products Offered
11.1.5 Mylan Pharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-Inflammatory Peptides Market Estimates and Projections by Region
12.1.1 Global Anti-Inflammatory Peptides Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-Inflammatory Peptides Revenue Forecast by Regions 2021-2026
12.2 North America Anti-Inflammatory Peptides Market Size Forecast (2021-2026)
12.2.1 North America: Anti-Inflammatory Peptides Sales Forecast (2021-2026)
12.2.2 North America: Anti-Inflammatory Peptides Revenue Forecast (2021-2026)
12.2.3 North America: Anti-Inflammatory Peptides Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-Inflammatory Peptides Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-Inflammatory Peptides Sales Forecast (2021-2026)
12.3.2 Europe: Anti-Inflammatory Peptides Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-Inflammatory Peptides Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-Inflammatory Peptides Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-Inflammatory Peptides Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-Inflammatory Peptides Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-Inflammatory Peptides Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-Inflammatory Peptides Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-Inflammatory Peptides Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-Inflammatory Peptides Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-Inflammatory Peptides Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-Inflammatory Peptides Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-Inflammatory Peptides Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-Inflammatory Peptides Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-Inflammatory Peptides Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anti-Inflammatory Peptides Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-Inflammatory Peptides Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Anti-Inflammatory Peptides Market Segments
Table 2. Ranking of Global Top Anti-Inflammatory Peptides Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anti-Inflammatory Peptides Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Cardiovascular Diseases
Table 5. Major Manufacturers of Gastrointestinal Diseases
Table 6. Major Manufacturers of Dermatological Diseases
Table 7. Major Manufacturers of Neurological Diseases
Table 8. Major Manufacturers of Otorhino Diseases & Ophthalmological
Table 9. Major Manufacturers of Respiratory Diseases & Pulmonary
Table 10. Major Manufacturers of Renal Diseases
Table 11. Major Manufacturers of Rheumatological & Autoimmune Diseases
Table 12. Major Manufacturers of Transplantation
Table 13. Global Anti-Inflammatory Peptides Market Size Growth Rate by Application 2020-2026 (K Units)
Table 14. Global Anti-Inflammatory Peptides Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 15. Global Anti-Inflammatory Peptides Sales by Regions 2015-2020 (K Units)
Table 16. Global Anti-Inflammatory Peptides Sales Market Share by Regions (2015-2020)
Table 17. Global Anti-Inflammatory Peptides Revenue by Regions 2015-2020 (US$ Million)
Table 18. Global Anti-Inflammatory Peptides Sales by Manufacturers (2015-2020) (K Units)
Table 19. Global Anti-Inflammatory Peptides Sales Share by Manufacturers (2015-2020)
Table 20. Global Anti-Inflammatory Peptides Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 21. Global Anti-Inflammatory Peptides by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Inflammatory Peptides as of 2019)
Table 22. Anti-Inflammatory Peptides Revenue by Manufacturers (2015-2020) (US$ Million)
Table 23. Anti-Inflammatory Peptides Revenue Share by Manufacturers (2015-2020)
Table 24. Key Manufacturers Anti-Inflammatory Peptides Price (2015-2020) (USD/Unit)
Table 25. Anti-Inflammatory Peptides Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Anti-Inflammatory Peptides Product Type
Table 27. Date of International Manufacturers Enter into Anti-Inflammatory Peptides Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Anti-Inflammatory Peptides Sales by Type (2015-2020) (K Units)
Table 30. Global Anti-Inflammatory Peptides Sales Share by Type (2015-2020)
Table 31. Global Anti-Inflammatory Peptides Revenue by Type (2015-2020) (US$ Million)
Table 32. Global Anti-Inflammatory Peptides Revenue Share by Type (2015-2020)
Table 33. Anti-Inflammatory Peptides Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 34. Global Anti-Inflammatory Peptides Sales by Application (2015-2020) (K Units)
Table 35. Global Anti-Inflammatory Peptides Sales Share by Application (2015-2020)
Table 36. North America Anti-Inflammatory Peptides Sales by Country (2015-2020) (K Units)
Table 37. North America Anti-Inflammatory Peptides Sales Market Share by Country (2015-2020)
Table 38. North America Anti-Inflammatory Peptides Revenue by Country (2015-2020) (US$ Million)
Table 39. North America Anti-Inflammatory Peptides Revenue Market Share by Country (2015-2020)
Table 40. North America Anti-Inflammatory Peptides Sales by Type (2015-2020) (K Units)
Table 41. North America Anti-Inflammatory Peptides Sales Market Share by Type (2015-2020)
Table 42. North America Anti-Inflammatory Peptides Sales by Application (2015-2020) (K Units)
Table 43. North America Anti-Inflammatory Peptides Sales Market Share by Application (2015-2020)
Table 44. Europe Anti-Inflammatory Peptides Sales by Country (2015-2020) (K Units)
Table 45. Europe Anti-Inflammatory Peptides Sales Market Share by Country (2015-2020)
Table 46. Europe Anti-Inflammatory Peptides Revenue by Country (2015-2020) (US$ Million)
Table 47. Europe Anti-Inflammatory Peptides Revenue Market Share by Country (2015-2020)
Table 48. Europe Anti-Inflammatory Peptides Sales by Type (2015-2020) (K Units)
Table 49. Europe Anti-Inflammatory Peptides Sales Market Share by Type (2015-2020)
Table 50. Europe Anti-Inflammatory Peptides Sales by Application (2015-2020) (K Units)
Table 51. Europe Anti-Inflammatory Peptides Sales Market Share by Application (2015-2020)
Table 52. Asia Pacific Anti-Inflammatory Peptides Sales by Region (2015-2020) (K Units)
Table 53. Asia Pacific Anti-Inflammatory Peptides Sales Market Share by Region (2015-2020)
Table 54. Asia Pacific Anti-Inflammatory Peptides Revenue by Region (2015-2020) (US$ Million)
Table 55. Asia Pacific Anti-Inflammatory Peptides Revenue Market Share by Region (2015-2020)
Table 56. Asia Pacific Anti-Inflammatory Peptides Sales by Type (2015-2020) (K Units)
Table 57. Asia Pacific Anti-Inflammatory Peptides Sales Market Share by Type (2015-2020)
Table 58. Asia Pacific Anti-Inflammatory Peptides Sales by Application (2015-2020) (K Units)
Table 59. Asia Pacific Anti-Inflammatory Peptides Sales Market Share by Application (2015-2020)
Table 60. Latin America Anti-Inflammatory Peptides Sales by Country (2015-2020) (K Units)
Table 61. Latin America Anti-Inflammatory Peptides Sales Market Share by Country (2015-2020)
Table 62. Latin Americaa Anti-Inflammatory Peptides Revenue by Country (2015-2020) (US$ Million)
Table 63. Latin America Anti-Inflammatory Peptides Revenue Market Share by Country (2015-2020)
Table 64. Latin America Anti-Inflammatory Peptides Sales by Type (2015-2020) (K Units)
Table 65. Latin America Anti-Inflammatory Peptides Sales Market Share by Type (2015-2020)
Table 66. Latin America Anti-Inflammatory Peptides Sales by Application (2015-2020) (K Units)
Table 67. Latin America Anti-Inflammatory Peptides Sales Market Share by Application (2015-2020)
Table 68. Middle East and Africa Anti-Inflammatory Peptides Sales by Country (2015-2020) (K Units)
Table 69. Middle East and Africa Anti-Inflammatory Peptides Sales Market Share by Country (2015-2020)
Table 70. Middle East and Africa Anti-Inflammatory Peptides Revenue by Country (2015-2020) (US$ Million)
Table 71. Middle East and Africa Anti-Inflammatory Peptides Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Anti-Inflammatory Peptides Sales by Type (2015-2020) (K Units)
Table 73. Middle East and Africa Anti-Inflammatory Peptides Sales Market Share by Type (2015-2020)
Table 74. Middle East and Africa Anti-Inflammatory Peptides Sales by Application (2015-2020) (K Units)
Table 75. Middle East and Africa Anti-Inflammatory Peptides Sales Market Share by Application (2015-2020)
Table 76. Mylan Pharmaceuticals Corporation Information
Table 77. Mylan Pharmaceuticals Description and Major Businesses
Table 78. Mylan Pharmaceuticals Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Mylan Pharmaceuticals Product
Table 80. Mylan Pharmaceuticals Recent Development
Table 81. Novartis AG Corporation Information
Table 82. Novartis AG Description and Major Businesses
Table 83. Novartis AG Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Novartis AG Product
Table 85. Novartis AG Recent Development
Table 86. Rogne Bioscience Corporation Information
Table 87. Rogne Bioscience Description and Major Businesses
Table 88. Rogne Bioscience Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Rogne Bioscience Product
Table 90. Rogne Bioscience Recent Development
Table 91. Merck Serono Corporation Information
Table 92. Merck Serono Description and Major Businesses
Table 93. Merck Serono Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Merck Serono Product
Table 95. Merck Serono Recent Development
Table 96. F4 Pharma Corporation Information
Table 97. F4 Pharma Description and Major Businesses
Table 98. F4 Pharma Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. F4 Pharma Product
Table 100. F4 Pharma Recent Development
Table 101. Araim Pharmaceuticals, Inc. Corporation Information
Table 102. Araim Pharmaceuticals, Inc. Description and Major Businesses
Table 103. Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Araim Pharmaceuticals, Inc. Product
Table 105. Araim Pharmaceuticals, Inc. Recent Development
Table 106. Digna Biotech Corporation Information
Table 107. Digna Biotech Description and Major Businesses
Table 108. Digna Biotech Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Digna Biotech Product
Table 110. Digna Biotech Recent Development
Table 111. Abbvie Corporation Corporation Information
Table 112. Abbvie Corporation Description and Major Businesses
Table 113. Abbvie Corporation Anti-Inflammatory Peptides Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Abbvie Corporation Product
Table 115. Abbvie Corporation Recent Development
Table 116. Global Anti-Inflammatory Peptides Sales Forecast by Regions (2021-2026) (K Units)
Table 117. Global Anti-Inflammatory Peptides Sales Market Share Forecast by Regions (2021-2026)
Table 118. Global Anti-Inflammatory Peptides Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 119. Global Anti-Inflammatory Peptides Revenue Market Share Forecast by Regions (2021-2026)
Table 120. North America: Anti-Inflammatory Peptides Sales Forecast by Country (2021-2026) (K Units)
Table 121. North America: Anti-Inflammatory Peptides Revenue Forecast by Country (2021-2026) (US$ Million)
Table 122. Europe: Anti-Inflammatory Peptides Sales Forecast by Country (2021-2026) (K Units)
Table 123. Europe: Anti-Inflammatory Peptides Revenue Forecast by Country (2021-2026) (US$ Million)
Table 124. Asia Pacific: Anti-Inflammatory Peptides Sales Forecast by Region (2021-2026) (K Units)
Table 125. Asia Pacific: Anti-Inflammatory Peptides Revenue Forecast by Region (2021-2026) (US$ Million)
Table 126. Latin America: Anti-Inflammatory Peptides Sales Forecast by Country (2021-2026) (K Units)
Table 127. Latin America: Anti-Inflammatory Peptides Revenue Forecast by Country (2021-2026) (US$ Million)
Table 128. Middle East and Africa: Anti-Inflammatory Peptides Sales Forecast by Country (2021-2026) (K Units)
Table 129. Middle East and Africa: Anti-Inflammatory Peptides Revenue Forecast by Country (2021-2026) (US$ Million)
Table 130. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 131. Key Challenges
Table 132. Market Risks
Table 133. Main Points Interviewed from Key Anti-Inflammatory Peptides Players
Table 134. Anti-Inflammatory Peptides Customers List
Table 135. Anti-Inflammatory Peptides Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Inflammatory Peptides Product Picture
Figure 2. Global Anti-Inflammatory Peptides Sales Market Share by Type in 2020 & 2026
Figure 3. Cardiovascular Diseases Product Picture
Figure 4. Gastrointestinal Diseases Product Picture
Figure 5. Dermatological Diseases Product Picture
Figure 6. Neurological Diseases Product Picture
Figure 7. Otorhino Diseases & Ophthalmological Product Picture
Figure 8. Respiratory Diseases & Pulmonary Product Picture
Figure 9. Renal Diseases Product Picture
Figure 10. Rheumatological & Autoimmune Diseases Product Picture
Figure 11. Transplantation Product Picture
Figure 12. Global Anti-Inflammatory Peptides Sales Market Share by Application in 2020 & 2026
Figure 13. Hospital Use
Figure 14. Clinic Use
Figure 15. Household
Figure 16. Other
Figure 17. Anti-Inflammatory Peptides Report Years Considered
Figure 18. Global Anti-Inflammatory Peptides Market Size 2015-2026 (US$ Million)
Figure 19. Global Anti-Inflammatory Peptides Sales 2015-2026 (K Units)
Figure 20. Global Anti-Inflammatory Peptides Market Size Market Share by Region: 2020 Versus 2026
Figure 21. Global Anti-Inflammatory Peptides Sales Market Share by Region (2015-2020)
Figure 22. Global Anti-Inflammatory Peptides Sales Market Share by Region in 2019
Figure 23. Global Anti-Inflammatory Peptides Revenue Market Share by Region (2015-2020)
Figure 24. Global Anti-Inflammatory Peptides Revenue Market Share by Region in 2019
Figure 25. Global Anti-Inflammatory Peptides Sales Share by Manufacturer in 2019
Figure 26. The Top 10 and 5 Players Market Share by Anti-Inflammatory Peptides Revenue in 2019
Figure 27. Anti-Inflammatory Peptides Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Anti-Inflammatory Peptides Sales Market Share by Type (2015-2020)
Figure 29. Global Anti-Inflammatory Peptides Sales Market Share by Type in 2019
Figure 30. Global Anti-Inflammatory Peptides Revenue Market Share by Type (2015-2020)
Figure 31. Global Anti-Inflammatory Peptides Revenue Market Share by Type in 2019
Figure 32. Global Anti-Inflammatory Peptides Market Share by Price Range (2015-2020)
Figure 33. Global Anti-Inflammatory Peptides Sales Market Share by Application (2015-2020)
Figure 34. Global Anti-Inflammatory Peptides Sales Market Share by Application in 2019
Figure 35. Global Anti-Inflammatory Peptides Revenue Market Share by Application (2015-2020)
Figure 36. Global Anti-Inflammatory Peptides Revenue Market Share by Application in 2019
Figure 37. North America Anti-Inflammatory Peptides Sales Growth Rate 2015-2020 (K Units)
Figure 38. North America Anti-Inflammatory Peptides Revenue Growth Rate 2015-2020 (US$ Million)
Figure 39. North America Anti-Inflammatory Peptides Sales Market Share by Country in 2019
Figure 40. North America Anti-Inflammatory Peptides Revenue Market Share by Country in 2019
Figure 41. U.S. Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 42. U.S. Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Canada Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 44. Canada Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. North America Anti-Inflammatory Peptides Market Share by Type in 2019
Figure 46. North America Anti-Inflammatory Peptides Market Share by Application in 2019
Figure 47. Europe Anti-Inflammatory Peptides Sales Growth Rate 2015-2020 (K Units)
Figure 48. Europe Anti-Inflammatory Peptides Revenue Growth Rate 2015-2020 (US$ Million)
Figure 49. Europe Anti-Inflammatory Peptides Sales Market Share by Country in 2019
Figure 50. Europe Anti-Inflammatory Peptides Revenue Market Share by Country in 2019
Figure 51. Germany Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 52. Germany Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. France Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 54. France Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. U.K. Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 56. U.K. Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Italy Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 58. Italy Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Russia Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 60. Russia Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Europe Anti-Inflammatory Peptides Market Share by Type in 2019
Figure 62. Europe Anti-Inflammatory Peptides Market Share by Application in 2019
Figure 63. Asia Pacific Anti-Inflammatory Peptides Sales Growth Rate 2015-2020 (K Units)
Figure 64. Asia Pacific Anti-Inflammatory Peptides Revenue Growth Rate 2015-2020 (US$ Million)
Figure 65. Asia Pacific Anti-Inflammatory Peptides Sales Market Share by Region in 2019
Figure 66. Asia Pacific Anti-Inflammatory Peptides Revenue Market Share by Region in 2019
Figure 67. China Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 68. China Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Japan Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 70. Japan Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. South Korea Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 72. South Korea Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. India Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 74. India Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Australia Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 76. Australia Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Taiwan Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 78. Taiwan Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Indonesia Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 80. Indonesia Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Thailand Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 82. Thailand Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Malaysia Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 84. Malaysia Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Philippines Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 86. Philippines Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Vietnam Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 88. Vietnam Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Asia Pacific Anti-Inflammatory Peptides Market Share by Type in 2019
Figure 90. Asia Pacific Anti-Inflammatory Peptides Market Share by Application in 2019
Figure 91. Latin America Anti-Inflammatory Peptides Sales Growth Rate 2015-2020 (K Units)
Figure 92. Latin America Anti-Inflammatory Peptides Revenue Growth Rate 2015-2020 (US$ Million)
Figure 93. Latin America Anti-Inflammatory Peptides Sales Market Share by Country in 2019
Figure 94. Latin America Anti-Inflammatory Peptides Revenue Market Share by Country in 2019
Figure 95. Mexico Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 96. Mexico Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Brazil Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 98. Brazil Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Argentina Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 100. Argentina Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Latin America Anti-Inflammatory Peptides Market Share by Type in 2019
Figure 102. Latin America Anti-Inflammatory Peptides Market Share by Application in 2019
Figure 103. Middle East and Africa Anti-Inflammatory Peptides Sales Growth Rate 2015-2020 (K Units)
Figure 104. Middle East and Africa Anti-Inflammatory Peptides Revenue Growth Rate 2015-2020 (US$ Million)
Figure 105. Middle East and Africa Anti-Inflammatory Peptides Sales Market Share by Country in 2019
Figure 106. Middle East and Africa Anti-Inflammatory Peptides Revenue Market Share by Country in 2019
Figure 107. Turkey Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 108. Turkey Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Saudi Arabia Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 110. Saudi Arabia Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. U.A.E Anti-Inflammatory Peptides Sales Growth Rate (2015-2020) (K Units)
Figure 112. U.A.E Anti-Inflammatory Peptides Revenue Growth Rate (2015-2020) (US$ Million)
Figure 113. Middle East and Africa Anti-Inflammatory Peptides Market Share by Type in 2019
Figure 114. Middle East and Africa Anti-Inflammatory Peptides Market Share by Application in 2019
Figure 115. North America Anti-Inflammatory Peptides Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. North America Anti-Inflammatory Peptides Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Europe Anti-Inflammatory Peptides Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Europe Anti-Inflammatory Peptides Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Asia Pacific Anti-Inflammatory Peptides Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. Asia Pacific Anti-Inflammatory Peptides Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Latin America Anti-Inflammatory Peptides Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 122. Latin America Anti-Inflammatory Peptides Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Middle East and Africa Anti-Inflammatory Peptides Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 124. Middle East and Africa Anti-Inflammatory Peptides Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Porter's Five Forces Analysis
Figure 126. Channels of Distribution
Figure 127. Distributors Profiles
Figure 128. Bottom-up and Top-down Approaches for This Report
Figure 129. Data Triangulation
Figure 130. Key Executives Interviewed
免疫介在性炎症性疾患治療の世界市場（～2026年） Immune-Mediated Inflammatory Diseases Treatment is any of a group of conditions or diseases that lack a definitive etiology, but which are characterized by common inflammatory pathways leading to inflammation, and which may result from, or be triggered by, a dysregulation of the normal immune respon…- 希少性肺疾患治療の世界市場（～2026年） Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists. Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are e…
- 動物用自己免疫疾患検査の世界市場（～2026年） Animal autoimmune diseases are the result of specific immune responses and directed against self. Animals have the ability to control immune aggression. It acquired the capacity to avoid self-reaction called as tolerance, which allows removal of antigenic pathogens in the absence of self-recognition…
- 希少疾患の世界市場（～2026年） An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases hav…
- 運動ニューロン疾患治療の世界市場（～2026年） Market Analysis and Insights: Global Motor Neuron Diseases Treatment Market The global Motor Neuron Diseases Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Motor Neuron Diseases Treatment Scope and Market Si…